NT5E and non-small cell lung carcinoma: Clinical observations up to July 2021 were published in 2023 for patients with T790M-negative EGFRm NSCLC and showed CBR of 75% and OR of 25% in five patients receiving 1500 mg anti-CD73 antibody; CBR of 82.4% and OR of 11.8% were noted in 21 patients administered 3000 mg anti-CD73 antibody (35).